Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
March 15, 2023 at 06:00 pm IST
Share
Compass Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 11.59 million compared to USD 12.98 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.15 a year ago. Diluted loss per share from continuing operations was USD 0.1 compared to USD 0.15 a year ago.
For the full year, the company reported net loss was USD 39.23 million compared to USD 82.18 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 1.31 a year ago. Diluted loss per share from continuing operations was USD 0.37 compared to USD 1.31 a year ago.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.